Cancer3.AICancer TherapiesHematopoietic stem cell transplantation › Autologous stem cell transplantation

Autologous stem cell transplantation

In an autologous transplant, the patient's own blood-forming stem cells are collected and frozen before high-dose chemotherapy, then returned by infusion to rebuild the bone marrow. Because the cells are the patient's own, there is no rejection and no graft-versus-host disease, although a small risk remains that cancer cells are returned together with the graft. It is a standard consolidation treatment in multiple myeloma and is also used in some lymphomas and in selected childhood solid tumors such as neuroblastoma.

How it works

The patient's blood-forming stem cells are first collected from the blood or bone marrow, then frozen and stored. The patient next receives high-dose chemotherapy, sometimes with radiation, aimed at destroying the cancer — at doses so intensive that they also destroy the bone marrow. The thawed cells are then given back through a vein, much like a blood transfusion; they travel to the bones and over the following weeks resume producing blood cells. The transplant itself does not attack the cancer — its role is to make very intensive treatment possible by restoring the marrow afterwards. Until the graft starts working, blood counts are very low and the patient needs protection against infection and bleeding; full recovery of the immune system after an autologous transplant usually takes several months.

Used in

Primary CNS Lymphoma C71

Consolidation after methotrexate-based induction in younger, fit patients — an alternative to whole-brain radiotherapy with its late neurotoxicity.

Hodgkin Lymphoma (HL) C81

Relapsed or refractory Hodgkin lymphoma after effective salvage chemotherapy — undertaken with curative intent.

B-Cell Lymphomas (non-Hodgkin) C82-C85, C88, C91

Relapsed chemosensitive diffuse large B-cell lymphoma; in early relapse CAR-T therapy has displaced it for a subset of indications.

Plasma Cell Neoplasms C90

High-dose melphalan consolidation with autologous rescue in transplant-eligible myeloma patients — part of standard first-line treatment.

Testis C62

High-dose chemotherapy with autologous rescue in salvage treatment of relapsed germ cell tumours after failure of standard therapy.

Where this therapy is delivered

Sources

  1. NCI – Stem Cell Transplants in Cancer Treatment ↗
  2. NCI PDQ – Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (Patient Version) ↗